Brought to you by 
Codexis, Nestle Health Science team up in metabolic diseases
10 Jan 2020
Executive Summary
Codexis Inc. granted Nestle Health Science SA an option to license exclusive worldwide development and commercialization rights to its CDX6114 for phenylketonuria (PKU). Nestle also receives access to Codexis' CodeEvolver protein engineering platform for use in discovering therapies for other metabolic disorders and for the development of enzyme products for Nestle's medical nutrition and consumer care businesses.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Codexis, Nestle Health Science team up in metabolic diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice